NurExone reports consistent lab anti-inflammatory activity across three exosome batches
NurExone Biologic reported lab results showing similar anti-inflammatory activity across three nave exosome batches, supporting ExoPTEN and Exo-Top plans.
Elton Resources completes $3.47 million flow-through financing
Elton Resources completed a $3.47 million flow-through unit private placement, issuing 15.78 million units; final TSX Venture Exchange approval pending.